Biotechnology - Neurological, Novartis

Filter

Current filters:

NeurologicalNovartis

Popular Filters

Clinical briefs from Novartis, Gilead and AstraZeneca

13-11-2012

Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

News briefs from Sanofi, Biogen/SOBI and Novartis

01-11-2012

French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

14-10-2012

New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch

28-09-2012

The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) Tysabri (natalizumab).…

AubagioBiogen IdecBiotechnologyElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalSanofiTysabri

GenVec extends research deal with Novartis

29-01-2012

US biopharma company GenVec (Nasdaq: GNVC) says that it has extended its research collaboration and license…

BiotechnologyGenVecNeurologicalNovartisPharmaceuticalResearch

EMA starts review of Gilenya; guidance on biosimilar interferon beta

23-01-2012

The European Medicines Agency has begun a review of the benefits and risks of Swiss drug major Novartis’…

BiotechnologyEuropeGenericsGilenyainterferon betaNeurologicalNovartisPharmaceuticalRegulation

Novartis in licensing deal with Cellectis; pays milestone to GenVec

07-12-2011

Paris, France-based Cellectis genome engineering specialist (Alternext: ALCLS) has signed a license agreement…

BiotechnologyCellectisGenVecLicensingNeurologicalNovartisPharmaceutical

Parexel

Parexel

Back to top